MedDataX Logo

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

NCT ID: NCT00443534

Last Updated: 2013-05-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

123 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

NCT00511849

Neoplasms
COMPLETED PHASE1

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

NCT00428220

Metastatic Breast Cancer Advanced Breast Cancer Metastatic Castration Resistant Prostate Cancer +9 more
COMPLETED NA

Treatment With SU11248 in Patients With Neuroendocrine Tumors

NCT00056693

Neuroendocrine Tumors
COMPLETED PHASE2

Rollover Protocol for Prior SU011248 Protocols

NCT00798889

Solid Tumors
COMPLETED NA

Efficacy of SU 011248 in Head And Neck Carcinoma

NCT00408252

Recurrent Disease Squamous Cell Head and Neck Carcinoma Palliative Treatment
TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

SU011248

Intervention Type DRUG

Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SU011248

Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sutent/Sunitinib

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participation in a previous SU011248 protocol and are judged by the investigator to have the potential to derive clinical benefit by remaining on SU011248 after the prior protocol ends.

Exclusion Criteria

* Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Aurora, Colorado, United States

Site Status

Pfizer Investigational Site

Littleton, Colorado, United States

Site Status

Pfizer Investigational Site

Orlando, Florida, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Harvey, Illinois, United States

Site Status

Pfizer Investigational Site

Harvey, Illinois, United States

Site Status

Pfizer Investigational Site

Maywood, Illinois, United States

Site Status

Pfizer Investigational Site

Tinley Park, Illinois, United States

Site Status

Pfizer Investigational Site

Zion, Illinois, United States

Site Status

Pfizer Investigational Site

Munster, Indiana, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Grand Rapids, Michigan, United States

Site Status

Pfizer Investigational Site

City of Saint Peters, Missouri, United States

Site Status

Pfizer Investigational Site

Creve Coeur, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

Las Vegas, Nevada, United States

Site Status

Pfizer Investigational Site

Hackensack, New Jersey, United States

Site Status

Pfizer Investigational Site

Chapel Hill, North Carolina, United States

Site Status

Pfizer Investigational Site

Clinton, North Carolina, United States

Site Status

Pfizer Investigational Site

Goldsboro, North Carolina, United States

Site Status

Pfizer Investigational Site

Hickory, North Carolina, United States

Site Status

Pfizer Investigational Site

Wilson, North Carolina, United States

Site Status

Pfizer Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Pfizer Investigational Site

Tulsa, Oklahoma, United States

Site Status

Pfizer Investigational Site

Tulsa, Oklahoma, United States

Site Status

Pfizer Investigational Site

Tulsa, Oklahoma, United States

Site Status

Pfizer Investigational Site

Hershey, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Greenville, South Carolina, United States

Site Status

Pfizer Investigational Site

Greer, South Carolina, United States

Site Status

Pfizer Investigational Site

Spartanburg, South Carolina, United States

Site Status

Pfizer Investigational Site

Bedford, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Fort Worth, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Edmonton, Alberta, Canada

Site Status

Pfizer Investigational Site

Ottawa, Ontario, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Lyon, , France

Site Status

Pfizer Investigational Site

Marseille, , France

Site Status

Pfizer Investigational Site

Villejuif, , France

Site Status

Pfizer Investigational Site

Berlin, , Germany

Site Status

Pfizer Investigational Site

Großhansdorf, , Germany

Site Status

Pfizer Investigational Site

Hamburg, , Germany

Site Status

Pfizer Investigational Site

Wiesbaden, , Germany

Site Status

Pfizer Investigational Site

Bologna, , Italy

Site Status

Pfizer Investigational Site

Cremona, , Italy

Site Status

Pfizer Investigational Site

Genova, , Italy

Site Status

Pfizer Investigational Site

Milan, , Italy

Site Status

Pfizer Investigational Site

Orbassano (TO), , Italy

Site Status

Pfizer Investigational Site

Rozzano (MI), , Italy

Site Status

Pfizer Investigational Site

Elche, Alicante, Spain

Site Status

Pfizer Investigational Site

Barcelona, Barcelona, Spain

Site Status

Pfizer Investigational Site

Córdoba, Cordoba, Spain

Site Status

Pfizer Investigational Site

Sutton, Surrey, United Kingdom

Site Status

Pfizer Investigational Site

London, , United Kingdom

Site Status

Pfizer Investigational Site

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada France Germany Italy Spain United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181078&StudyName=A%20Treatment%20Protocol%20For%20Patients%20Continuing%20From%20A%20Prior%20SU011248%20Protocol.

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A6181078

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
NCT00094029 APPROVED_FOR_MARKETING
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
NCT00393796 TERMINATED PHASE2
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial
NCT00578526 COMPLETED PHASE2
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
NCT00113516 COMPLETED PHASE2
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
NCT00137449 COMPLETED PHASE2
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
NCT00092001 COMPLETED PHASE2
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
NCT00270413 COMPLETED PHASE2
Study of SU11248 in Men With Advanced Prostate Cancer
NCT00299741 COMPLETED PHASE2
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
NCT00054886 COMPLETED PHASE2
A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
NCT00615446 COMPLETED PHASE1
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
NCT00712504 COMPLETED PHASE1
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT00451048 COMPLETED PHASE2
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
NCT00137436 COMPLETED PHASE1/PHASE2
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
NCT00783653 COMPLETED PHASE1/PHASE2
A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
NCT00531544 COMPLETED NA
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
NCT02048371 COMPLETED PHASE2
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
NCT00329043 ACTIVE_NOT_RECRUITING PHASE2
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
NCT00528619 COMPLETED PHASE1
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
NCT00400569 COMPLETED PHASE2
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
NCT00372775 COMPLETED PHASE2
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
NCT00077974 COMPLETED PHASE2
SU011248 in Advanced Hepatocellular Carcinoma
NCT00361309 COMPLETED PHASE2
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
NCT01402817 TERMINATED PHASE2
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
NCT00130897 APPROVED_FOR_MARKETING
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
NCT00535379 UNKNOWN PHASE2